Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

dazucorilant

PharmaDeviceNews dazucorilant

Representative image: Corcept Therapeutics’ dazucorilant survival signal in amyotrophic lateral sclerosis highlights how ALS clinical trials are shifting attention from short-term functional scores to longer-term survival outcomes.

Pharma & Biotech

A failed ALS trial still showed a stunning survival signal. Can Corcept turn it into Phase 3 proof?

by Pallavi Madhiraju
May 3, 2026
0 Comments

A failed ALS endpoint meets a striking survival signal. Corcept now faces the harder test: proving dazucorilant in Phase 3.

Read More

Latest news and features

Withings BeamO can now send heart sounds to FDA-cleared AI for murmur analysis
InnovHeart performs first U.S. Saturn transseptal mitral valve replacement
Acepodia gets FDA clearance to test a two-payload ADC in advanced liver cancer
AbbVie’s new multiple myeloma bispecific posts 74% response rate versus 45.7% with standard therapy
FDA approves AstraZeneca Etcamah after ctDNA detects breast cancer resistance before scans
Mainstay ReActiv8 sustains chronic low back pain gains through two years in RESTORE trial
WHO lists Cepheid Xpert Hemorrhagic Fever Panel for Ebola response in Democratic Republic of the Congo
eGenesis pig kidneys keep three patients dialysis-free beyond eight months as pivotal trial approaches
Stoke and Biogen report four-year zorevunersen data showing durable Dravet seizure reductions
FDA approves Ionis ZANVASTRO as first disease-modifying treatment for Alexander disease
One cardiac MRI can take an hour to measure manually. Heartvue has FDA clearance to automate much of that work
Nyxoah Genio hits both pivotal endpoints in sleep apnea patients excluded from current U.S. neurostimulation

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.

Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

June 9, 2026

Latest business and industry news

Euro Sun Mining (TSX: ESM) lines up US$400m Rovina Valley debt framework
Peter Warren’s (ASX: PWR) A$28m Wakeling deal clears ACCC after eight-dealership remedy
China ballistic missile test fractures Pacific consensus at Palau summit
Hyundai Mobis opens KRW250bn Slovakia EV plant with 280,000-system capacity
Hanwha Ocean wins KRW1.55tn Yang Ming order for six LNG container ships

TAGS

clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immuno-oncology immunotherapy Inc. Johnson & Johnson medical devices oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration US Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.